# OnCo record nct05351788 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05351788/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05351788", "NCT05351788" ;
  schema:name "SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer."@en ;
  schema:description "A phase 2 trial of Sacituzumab tirumotecan, KL-A167, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05351788/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05351788> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2022-05-20" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/kl-a167/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/kelun-biotech/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05351788-nat-med-2025/> .